To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
GlycoErase™ PGK1 knockout glycoengineered cell disrupts phosphoglycerate kinase 1, a glycolytic enzyme that also functions in angiogenesis and as a moonlighting protein. Deficiency causes hemolytic anemia and neurological impairment. This model supports research in glycolysis, angiogenesis, and tumor biology.
Product Type
KO Cell Lines
Cell Line
As requested by the client.
Specification
Cell Viability
>90%
Sterility Test
The sterility test indicated an absence of microbial growth.
Identity Test
STR identification
Mycoplasma Test
Negative
Virus Test
Negative for HIV, HBV and HCV.
Genetic Stability Testing
We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation
PCR, Sanger Sequencing
Application
Functional assay
Size
1 M cells/vial*2
Product Format
Frozen
Shipping
Dry ice
Availability Status
Made to order
Handling Notes
Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer
This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.
The protein encoded by this gene is a glycolytic enzyme that catalyzes the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate. The encoded protein may also act as a cofactor for polymerase alpha. Additionally, this protein is secreted by tumor cells where it participates in angiogenesis by functioning to reduce disulfide bonds in the serine protease, plasmin, which consequently leads to the release of the tumor blood vessel inhibitor angiostatin. The encoded protein has been identified as a moonlighting protein based on its ability to perform mechanistically distinct functions. Deficiency of the enzyme is associated with a wide range of clinical phenotypes hemolytic anemia and neurological impairment. Pseudogenes of this gene have been defined on chromosomes 19, 21 and the X chromosome.